pharma is the sole category represented across all 1 tracked stories. DePuy Synthes is most often covered alongside Bank of America, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about DePuy Synthes
pharma is the sole category represented across all 1 tracked stories. DePuy Synthes is most often covered alongside Bank of America, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. We currently track 1 Biotech story that mention DePuy Synthes, all published on March 12, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering DePuy Synthes. Shared-story counts are live from our verified record — not editorial picks.
Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.
DePuy Synthes is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.